Subscribe To
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases Post-transaction cash, cash equivalents and investments of approximately $218 million expected to fund operations through 2026, including key data readouts from the Phase 2b trial in TED and the Phase 2 […] The post Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Pl...
Read More
Content Topics
Tourmaline
Announces
Closing
Merger
With
Talaris
Therapeutics
Concurrent
Private
Placement
Million
Forex
Posted: Oct 19 2023, 21:37
Author Name: forextv
Views: 082372